Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405690 | 1.00 | P2RX7 (0.54) | P2RX7TRPV1ROCK1KDM4EALDH1A1 | |
| SCHEMBL6403353 | 0.90 | P2RX7 (0.53) | P2RX7TRPV1 | |
| SCHEMBL6403395 | 0.90 | P2RX7 (0.53) | P2RX7TRPV1ROCK1 | |
| SCHEMBL6403349 | 0.90 | P2RX7 (0.53) | P2RX7TRPV1 | |
| SCHEMBL6403402 | 0.90 | P2RX7 (0.53) | P2RX7TRPV1ROCK1 | |
| SCHEMBL6400150 | 0.84 | P2RX7 (0.71) | P2RX7KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL6400149 | 0.84 | P2RX7 (0.71) | P2RX7KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL6405738 | 0.84 | P2RX7 (0.57) | P2RX7ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6405728 | 0.84 | P2RX7 (0.57) | P2RX7ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6401512 | 0.84 | P2RX7 (0.46) | P2RX7KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | claimed |
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | P2RX3, P2RX7, P2RX1 | P2RX7 2/4885TRPV1 15/4885ROCK1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.